The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1256
ISSUE1256
March 12, 2007
Paliperidone (Invega) for Schizophrenia
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Paliperidone (Invega) for Schizophrenia
March 12, 2007 (Issue: 1256)
Paliperidone (Invega - Janssen) has been approved by the FDA in an extended-release formulation for treatment of schizophrenia. It is the primary active metabolite of the second-generation antipsychotic risperidone (Risperdal - Janssen), which is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.